SEC Form 4 · accession 0001209191-17-019900
Flexion Therapeutics Inc · FLXN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael D. Clayman
Officer — President and CEO · Director
Period of report
Jun 21, 2016
Accepted (ET)
Mar 10, 2017 · 5:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001419600
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 21, 2016 | G | 15,722 | $0.00 | D | 15,146 | D | |
| Common Stock | Jun 21, 2016 | G | 15,722 | $0.00 | A | 294,383 | I | By the Michael D.Clayman 2006 Revocable Trust |
| Common Stock | holding | — | — | — | 24,600 | I | By the Michael D. Clayman Irrevocable Trust | |
| Common StockF1 | holding | — | — | — | 388,683 | I | By Versant Development Fund III, LLC |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares held by Versant Development Fund III, LLC. The Reporting Person is a manager and minority member of Versant Development Fund III, LLC. The Reporting Person disclaims any beneficial ownership of the shares held by Versant Development Fund III, LLC except to the extent of his pecuniary interest in these shares.